Regeneron Pharmaceuticals, Inc.

Healthcare · Biotechnology

Overall research band Strong

Quality Weak

Valuation Strong

Balance sheet Exceptional

Market confirmation Exceptional

One-minute company read

What this report can tell you now

What the company does

Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical company headquartered in Tarrytown, New York, focused on discovering, developing, manufacturing, and commercializing medical treatments for a broad range of diseases. Its main products include EYLEA for various ophthalmic conditions, Dupixent for atopic dermatitis and asthma, Libtayo for cutaneous squamous cell carcinoma, Praluent for hypercholesterolemia and cardiovascular disease, REGEN-COV for COVID-19, Kevzara for rheumatoid arthritis, Inmazeb for Zaire ebolavirus infections, ARCALYST for cryopyrin-associated periodic syndromes, and ZALTRAP for metastatic colorectal cancer. Regeneron serves patients with these conditions and generates revenue primarily through the sale of its pharmaceutical products. The company also engages in extensive collaborations and licensing agreements with partners such as Sanofi, Bayer, Teva, Mitsubishi Tanabe Pharma, Alnylam, Roche, Kiniksa, and various government and research organizations, supporting both its commercial and research activities.

The current research profile is Mixed Setup, with weak market confirmation. This is a starting point for investigation, not a forecast or recommendation.

Strongest visible signal

Recent market behavior is the strongest visible confirmation. Check whether it agrees with the underlying business evidence.

What to investigate next

Read the latest filing or company update, check the period behind the metrics, and investigate the dimension with the weakest band above.

Before you draw a conclusion

Read the latest filing or company update.
Check the financial period behind each metric.
Investigate the weakest score band and any missing evidence.

Headline fundamentals

A small set of signals worth checking

ROIC10.1%Model input; read with the evidence status and period context.

Operating margin24.3%Model input; read with the evidence status and period context.

Revenue CAGR · 4 years-2.8%Model input; read with the evidence status and period context.

FCF margin27.9%Model input; read with the evidence status and period context.

Go deeper when you need to

Compare the right companies, understand what changed, and monitor the evidence.

Peer contextCompare companies using the appropriate economic neighborhood.

Evidence detailSee exact inputs, source context, and model-aware metrics.

HistoryReview score and research changes over time.

MonitoringKeep the questions, risks, and changes that matter in view.

The public report remains useful on its own. Premium adds depth, history, comparison, and monitoring.